PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume Contents, Author index and Subject index to Volume 13

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors
Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology
Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics
Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
R. T. Brittain—*Ware, Hertfordshire*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*London, England*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1982, U.S. $700.00 including postage and insurance. 2 years, 1982/83, U.S. $1330.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3, 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1981 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear, copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 13, 1981, Numbers 1–3

CONTENTS

Number 1	PAGE
Evaluation of interferon and interferon inducers as antiviral agents: Animal studies: *E. R. Kern and L. A. Glasgow*	1
The influence of fragments of the LPH chains on learning, memory and attention in animals and man: *C. A. Sandman and A. J. Kastin*	39
Biosynthesis and control of secretion of corticotropic, lipotropic and melanotropic peptides: *F. E. Estivariz, G. Gillies and P. J. Lowry*	61
Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase: *P. V. Danenberg and A. Lockshin*	69
Present status of chemotherapy and chemoprophylaxis of animal trypanosomiasis in the eastern hemisphere: *T. M. Leach and C. J. Roberts*	91
Drug delivery systems: *F. Theeuwes*	149
General characteristics: Nomenclature of microbial toxins: *G. M. Thorne and S. L. Gorbach*	193
Genetic aspects of toxigenesis in bacteria: *W. K. Maas*	205
Number 2	
Current concepts on the mechanisms of action of antidepressant drugs: *M. F. Sugrue*	219
Antitoxic immunity in cholera and enterotoxigenic *Escherichia coli* (ETEC) diarrhea: *H. L. DuPont, D. G. Evans, D. J. Evans Jr, and T. K. Satterwhite*	249
The entomocidal toxins of *Bacillus thuringiensis: P. Luthy and H. R. Ebersold*	257
Clinical experience with beta adrenergic blocking agents in myocardial ischaemia: A dilemma and a challenge: *N. S. Baber*	285
Central nervous control of blood pressure in relation to antihypertensive drug treatment: *P. I. Korner and J. A. Angus*	321
Lipid composition and metabolism in normal and diseased epidermis: *H. J. Yardley and R. Summerly*	357
Number 3	
Analogs of pyrimidine and purine mononucleotide precursors as metabolic inhibitors: *E. Golovinsky and M. Spassova*	385
Pharmacokinetic studies of interferons: *V. Bocci*	421
Clostridium difficile toxin: *T. -W. Chang, J. G. Bartlett and N. S. Taylor*	441
Bacillus cereus toxins: *P. C. B. Turnbull*	453
E. coli heat-stable enterotoxin: *R. N. Greenberg and R. L. Guerrant*	507
Surgical procedures for the relief of pain: *J. Miles*	533
Estimation of pharmacokinetic parameters: Statistical considerations: *C. M. Metzler*	543

AUTHOR INDEX

Angus, J. A. 321

Baber, N. S. 285
Bartlett, J. G. 441
Bocci, V. 421

Chang, T. -W. 441

Danenberg, P. V. 69

Ebersold, H. R. 257
Estivariz, F. E. 61
Evans, D. G. 249
Evans, D. J. Jr. 249

Gillies, G. 61
Glasgow, L. A. 1
Golovinsky, E. 385
Gorbach, S. L. 193
Greenberg, R. N. 507
Guerrant, R. L. 507

Kastin, A. J. 39
Kern, E. R. 1
Korner, P. I. 321

Leach, T. M. 91
Lockshin, A. 69
Lowry, P. J. 61
Luthy, P. 257

Maas, W. K. 205
Metzler, C. M. 543
Miles, J. 533

Robert, C. J. 91

Sandman, C. A. 39
Satterwhite, T. K. 249
Spassova, M. 385
Sugrue, M. F. 219
Summerly, R. 357

Taylor, N. S. 441
Theeuwes, F. 149
Thorne, G. M. 193
Turnbull, P. C. B. 453

Yardley, H. J. 357

SUBJECT INDEX

Acebutolol and post-infarction arrhythmia 290
Acetazolamide
  release from elementary osmotic pumps 166–8
  side effects 169
Acne vulgaris and skin lipids 377
Acrodermatitis enteropathica, skin lipids 376, 377
Adenylate cyclase, brain activity and anti-depressants 235–7
ACTH *see* adrenocorticotrophin
Adrenocorticotrophin (ACTH) 39
  fragments, behaviour effects 39–44
  release and vasopressin 64
AIC triazeno analogues 403
AICRP analogues 405
  tetrazole 410
Alprenolol
  β-blocking activity and sustained release 163, 164
  delivery and formulation 161–3
  post-infarction trial 305
  and secondary prophylaxis 302–6
Animal studies
  interferon 1–32
  LPH fragments 39–58
  trypanosomiasis 91–137
Antibiotic associated colitis 449–51
  hamster 449
  pathology 449, 450
  treatment 450, 451
Antidepressants *see also* lithium, monoamine oxidase inhibitors 222–5
  acute effects on neurotransmitters 229, 230
  atypical 226, 227, 232–4
  and brain adenylate cyclase 235–7
  chronic receptor effects 231–4
  electrophysiology and behaviour 236, 237
  and monoamine turnover 225–9
  presynaptic changes 225–31
  tricyclic 225, 226, 231–4
Antiviral agents, evaluation in animals 1–32
Ara-C, infusion pump delivery 178
L-Aspartic acid analogues 385–9
Atenolol
  cardiac output 313
  and clinical outcome in myocardial infarction 299–302
Attention
  LPH effects 39–58
  model 56, 57

Bacillus cereus
  diarrhoea 481–90
  food poisoning 456, 457
  gastrointestinal survival 482
  infections 456
  isolates and vascular permeability reaction 489, 490
  metabolites as toxins 457, 460
  necrotic action 488
  pathogenicity 453–7
  toxins 453–500
B. cereus emetic toxin 497–500
  and *Bacillus* spp 500
  nature 497
  production 498
  temperature and reactivity 499
B. cereus haemolysins 467–77
  Bacillus spp producing 477
  cereolysin properties 467–9
  in vivo toxin 476
  mode of action 475, 476
  numbers 469, 470
  production 470–4
B. cereus lethal toxin 458–67
  activity persistence 462, 463
  growth media 463
  lethal activities 466, 467
  mode of action 463, 464
  protection 461
  species producing 464, 465
  strain differences 463
B. cereus loop fluid-inducing/ skin test necrotic toxin 481–97, 500
  assay and detection 494
  Bacillus spp producing 496, 497
  clinical importance 495, 496
  and diarrhoea 481
  mode of action 494, 495
  production 490–2
  stability 492–4
B. cereus phospholipases-C 477–81
  toxin activity 480
Bacillus thuringiensis 457
  active metabolites 260
  commercial preparations 260
  entomocidal toxins 257–79
  exoenzymes 279
  insects susceptible 259
  life cycle and biology 261, 262
  pathology of insect infections 257, 258
  varieties 262
B. thuringiensis alpha-exotoxin 279
B. thuringiensis beta-exotoxin
  chemisty 277
  insecticide use 278
  microbiology 278, 279
  mode of action 277, 278
  structure 277
B. thuringiensis delta-endotoxin
  biosynthesis 262, 263
  crystal activation by host 267–71
  crystal development 265, 266
  effect on *Pieris brassicae* gut 273
  and lactate dehydrogenase loss 275
  mode of action 271–6
  properties 276
  protein crystal composition 263–7
  in tissue culture cells 274
Bacteria
  and important toxins 194–7
  toxigenesis, genetics 205–14
Blocking agents
  antihypertensive mechanism 344–9
  β-adrenergic in myocardial ischaemia 285–316
  and blood pressure 344, 345
  cardiac output and heart rate 313
  chest pain relief 294, 295
  clinical outcome 299, 303
  CNS actions 346–8
  comparisons 290–3

effects on patient subgroups 310–15
evaluation 285
and infarct size 297–9
myocardium preservation 295–7
peripheral actions 345
post-infarction dysrhythmias 286–93
post-infarction mortality 307
post-infarction trials 303–6
prophylaxis of post-infarction dysrhythmias 293, 294
secondary prophylaxis 302–6
supraventricular dysrhythmias 289, 290
ventricular dysrhythmias 286–9
Blood pressure
arterial and renal nerves 327
β-blocker effects 344, 345
and carotid sinus pressure 328
CNS control and antihypertensives 321–50
field pulses and tachycardia 330
response to hypoxia 329
step disturbance, 'open-loop' effects 328

Cardiovascular control systems 322–32
components 322–5
and hypothalamic defense area 326
multiple afferent stimuli 325–7
Causalgia, surgical relief 536, 537
Cells, *Choristoneura fumiferana* and toxins 274, 275
Central nervous system
autonomic pathways 323
and heart rate in hypoxia 324
neurons, cardiovascular effects 332–9
resetting of arterial baroflex 327–9
Chemoprophylaxis in trypanosomiasis 91–131
camel 128
cattle 123–6
dogs and cats 128
equine 127, 128
risk evaluation 122, 123
sheep and goats 126
and slaughtering 124–6
Chemotherapy of trypanosomiasis in animals 97–137
history 97–100
and immune response 133–6
new agents 108–11
Cholera
antitoxic immunity 249–53
pathogenesis 249
vaccine, toxoid 251
Clonidine
CNS actions 340–3
mechanism of action 339–43
peripheral actions 339, 340
renal baroflex 341
Clostridium spp toxin nomenclature and properties 197
Clostridium difficile, occurrence 441
C. difficile cytotoxin
antitoxin neutralization 444–8
cell membrane actions 448
cytopathic effects 443, 444
microvilli effects 444–8
purification 442–3
stability 443
ultrastructural effects 444–8

Depression
5-hydroxytryptamine 221, 222
mechanism of action of drugs 219–39
monoamine role 219–22
norepinephrine 220, 221
Dihydroorotic acid analogues 391
Diminazene acetate 103
cross-resistance 130
formula 106
in trypanosomiasis 103, 106
Drug delivery systems 149–89
bleomycin 156, 157
elementary osmotic pump 164–8
feedback control 186–9
inert plastic matrix 159–64
infusion pumps 172–8
insulin 156
oral dosage forms 157–68
rate specifications 179–86
sustained release 158
transdermal 168–72
Drugs *see also* antidepressants, blocking agents
antidepressant, mechanism of action 219–39
antihypertensives and CNS control of blood pressure 339–50
controlled delivery, applications 155–7
doses 149
and gut transit time 160
serum concentrations and half-lives 150
trypanocidal 97–111
DTIC antitumour system 402

Eczema, skin lipids 377
Elderly, MSH/ACTH fragments effects 55
Electrical stimulation and pain relief 538–40
cerebral implant 540–2
Elementary osmotic pump 164–8
acetazolamide release 167
clinical trials 168
description 164, 165
rate performance 165–7
Endorphins
analgesia 44, 45
and development 45–51
in utero treatment 47–9
model of effects 56, 57
morphine sensitivity 49
neonatal injection 46
passive avoidance 48
and schizophrenia 55, 56
sensitivity threshold 46, 47
social behavior 48
Enkephalin 44
Epidermis
cell lipid composition 358
depth and lipids and glucose 357
essential fatty acids 369–77
lipid composition 357–61
lipid metabolism 361–5
lipids in disease 369–77
Escherichia coli diarrhea (ETEC)
antitoxic immunity 249–53
immunity 251–3
pathogenesis 249
serotypes and enterotoxin 519, 520
E. coli heat-stable (ST) enterotoxin 507–23
assay methods 510, 511
clinical presentation 508–10
and colonization 515, 516
effects 516–19
epidemiology 508–10
genetic control 513, 514
immunity 520, 521
intervention in mechanism of action 518
management of diarrhoea 521, 522
and pathology 514, 515
purification 512, 513
serotypes 519, 520
and travellers diarrhoea 509

Essential fatty acids in skin 366–9
deficiency effects 367, 368
origin 366, 367
role 368, 369
ETEC *see Escherichia coli*
Eye, viral infections 2–5

Fatty acids of pig epidermis 361
FdUMP and thymidylate synthetase inhibition 72–86
binding 74
kinetics 72, 73
nucleophilic binding group 80–3
nucleotide binding stoichiometry 83–6
reverse reaction mechanism 79, 80
sequence analysis 82, 83
ternary complex structure 74–9
5-Fluoroorotic acid (FOA) 392–4
molecular mechanisms 392, 393
Functional reciprocity 57, 58

Genetics, bacterial and toxin control
chromosomal 212, 213
phage 211, 212
plasmid 206–11
Genital tract, viral infections 7, 8
Glucose controlled insulin infusion systems (GCIIS) 187–9
normoglycemia 188, 189
rate performance 187, 188
Guanfacine 343

Homidium halides
cross-resistance 130
formula 105
in trypansomiasis 102, 105, 106
5-Hydroxytryptamine (serotonin) in depression 221, 222
Hypertension
autonomic effects and circulatory changes 331, 332
smooth muscle changes 331
Hypoxia
autonomic effects 324, 325
blood pressure response 329

Ichthyoses, acquired and skin lipids 376
Ichthyoses, inherited and skin lipids 374, 375
Imidazole analogues 400–6
structural 404
Immune response
enhancement 134, 135
nature of 133, 134
in trypanosomiasis 133–6
Infection
local viral 2–10
systemic and interferon treatment 10–23
Infusion pumps 172–8
ara-C delivery 178
elastomeric 175–7
heparin 174
implantable 174, 175
use in leukaemia 176, 178
vapour pressure pump properties 173
Inhibitors
mononucleotide precursor analogues 385–411
thymidylate synthetase 69–87
Interferon
animal studies 1–32
blood white cells and 431, 432
catabolism, kidney 426–9
liver 425, 426
muscle 419, 430
clearance 27, 28
economically important illness 23, 24
enhancement of induction 28, 29
gastrointestinal leakage 431
lung role 431
metabolism 422, 423
by endothelium 430, 431
pharmacokinetics 421–32
receptor binding and catabolism 423–5
role in pathogenesis 30, 31
target organ production 26, 27
viral sensitivity 25, 26
Interferon inducers 1–32
enhancement 28, 29
hyporeactivity 29, 30
Isometamidium hydrochloride
formula 107
in trypanosomiasis 103, 107, 108

Kidney, protein turnover 427

Learning, LPH fragment effects 39–58
Leukaemia, acute myelogenous and infusion pumps 176, 178
Lipids
catabolism in skin 365
epidermal in disease 369–77
pig epidermal 358
synthesis in skin
β-Lipotrophin (LPH), fragments, effects on learning and memory 39–58
Lithium
and adenylate cyclase 236
receptor binding 232
presynaptic changes 228, 229
serotoninergic receptors 234
LPH *see* β-lipotrophin

Mannich reaction 80
Matrix tablets
alprenolol delivery 161–3
β-blocking activity and alprenolol 163, 164
rate performance 160, 161
Melanocyte stimulating hormone (MSH/ACTH 4–9 analogue
behavioural effects 51, 52
effects in man 49–51
elderly 55
functional reciprocity 57, 58
in mentally retarded 54, 55
perceptual-attentional model 56, 57
and personality 53
sex effects 52, 53
Memory, LPH fragments effects 39–58
Mental retardation, MSH/ACTH analogue effects 54, 55
Metamidium, cross resistance 130
α-Methyl dopa, antihypertensive mechanism 343, 344
Mini-osmotic pump 151–3
rate performances 153–5
in vitro 154
in vivo 154, 155
Monoamine oxidase inhibitors 228, 232
and adenylate cyclase 235
and serotoninergic receptors 233

Monoamines
metabolism and enzymes 219, 220
role in depression 219–22
turnover and antidepressants 225–9
mononucleotide precursor analogues as inhibitors 385–411
MSH *see* melanocyte stimulating hormone
Multiple carboxylase deficiency syndrome, skin lipids in 377
Muscle, interferon catabolism 429, 430
Myocardial ischaemia
β-blockers, clinical experience 285–316
effects of β-blockade 296

Nephron, catabolic pathways 428, 429
Neurons, cardiovascular function of CNS
angiotensin 337, 338
catecholamine 333, 334
dopamine 333, 334
GABA 337
5-hydroxytryptamine 334–6
noradrenaline 336, 337
opioid peptides 338
Norepinephrine in depression 220, 221
Nucleotides, stoichiometry of binding 83–6

Orotic acid 386
analogues 391–8
antimetabolite forumla 392
Orotidine analogues 398

Pain
benign 536–42
cerebral stimulation 540–2
electrical stimulation sites 538, 539
malignant 533–6
nervous system destruction 533–6
surgery for relief 533–42
Peptide hormones
human volunteer effects 49–53
molecular weight and effects 41–3
pars distalis 61–6
pars intermedia 66
Peripheral nerve ablation in pain 534
Phage control of toxins 211, 212
Pharmacology
rate specifications 179–86
research tools 151–7
Pharmacokinetics
absorption rate 180–2
bleomycin 157
compartment models 543–5
computer programs 549–51
delivery rate 182, 183
drugs in gastrointestinal tract 184
interferon studies 421–32
numerical methods 448, 449
parameter estimation and statistics 543–54
rate specifications 179–86
research tools 151–7
statistical problems 545–7
statistical properties of estimates 551–4
structural variations 183–6
Phospholipids
pig epidermis 359
in psoriatic lesions 371
Pindolol, cardiac output and 313
Pituitary
adenoma cells, secretions 65
pars distalis peptides 61–6
pars intermedia peptides 66
potassium stimulation 62, 63
Plasmid, control of toxins 206–11
Practolol
and cardiac output 313
post-infarction trials 308, 309
secondary prophylaxis and myocardial infarction 304
Propranolol
antihypertensive mechanism 344–8
arrhythmia prophylaxis 293, 294
cardiac output 313
clinical outcome 299–302
and infarct size 297–9
patient subgroup effects 310, 311
post-infarction trials 306–8
serum levels in infarction 315
and ventricular dysrhythmias 286, 287
Pseudomembranous colitis 441
clinical features 449
pathology 449, 450
treatment 450, 451
Psoriasis, epidermal lipids 370–4
Purine biosynthesis 398, 399
Purine nucleoside monophosphate precursor antimetabolites 398–410
Pyrazole, analogues of cyclic precursors 406–9
Pyrimidine nucleoside
pathways of biosynthesis 385, 386
precursor analogues 385–98
Pyrithidium bromide
cross resistance 130
formula 107
in trypanosomiasis 103, 106, 107

Quinapyramine dimethosulfate
cross-resistance 130
in trypanosomiasis 102, 104, 105

Receptors and antidepressant action
adrenergic 222, 223, 231, 232
α_2-adrenergic 229, 230
cholinergic 224
histaminergic 223
imipramine 224
serotoninergic 223, 233
Resistance to drugs in trypanosomiasis
cross-resistance 129, 130
development 129
natural 128, 129
stability 131
Respiratory tract, viral infections 8–10

Schizophrenia and endorphins 55
Scopolamine
and motion sickness 172
transdermal therapeutic system 170–2
urinary excretion and effects 170, 171
Sensory root destruction 534
Skin *see also* epidermis
permeability and transdermal drug delivery 168, 169
virus infections and interferon 5–7
Sotalol, post-infarction effects 288
Sphingolipids, pig epidermis 359, 360
Staphylococcus aureus toxin nomenclature and properties 196
Sterols, pig epidermis 360, 361
Suramin and complexes in trypanosomiasis 101, 102, 104

Surgery
cordotomy 534
myelotomy 535
pain relief 533–42
sites for pain relief 534
tractotomy 535

Thymidylate synthetase
enzyme mechanisms 70–2
FdUMP interaction 72–86
inhibitors 69–87 *see also* FdUMP
reaction catalyzed 69
reaction intermediates 70, 71
5-trifluoromethyl-2′-deoxyuridylate 86, 87
Toxigenesis, genetics in bacteria 205–14
Toxins 193–201, 205
Bacillus cereus 453–500
bacterial 194–7
chromosomal control 212, 213
Clostridium difficile 441–51
entomocidal 257–79
enzyme activity 199
Escherichia coli 507–23
genes, bioprocessing 206
immunity in diarrhoea 249–53
molecular structure 200, 201
nomenclature 193–201
phage controlled 211, 212
plasmid controlled 206–11
properties 194–7
purification 198
toxicity 194–7
toxicity assessment 198, 199
toxigenicity 199, 200
Transcutaneous electrical stimulation 538, 539
Transdermal drug delivery 168–72
scopolamine 170–2
Triazole analogues as purine cyclic precursors 409, 410
5-Trifluoromethyl-2′-deoxyuridylate, thymidylate synthetase interaction 86, 88
Trigeminal neuralgia, surgical relief 537, 538
Trypanosoma brucei 117, 119, 123, 127
T. congolense 116, 117, 119, 123, 127
T. equiperdum 120, 121, 128
T. evansi 117–19, 121, 126, 127
T. simiae 118, 119
T. vivax 116, 117, 119, 123, 127

Trypanosomes
blood stream forms 92
diseases caused 96, 97
drugs 97–111
host and pathogenicity 95, 96
hosts and transmission 92
pathogenicity 93, 94
vector effects 94, 95
Trypanosomiasis
camel 121
cattle 115–18
chemotherapy and chemoprophylaxis in animals 92–137
diagnosis in animals 111–15
dogs and cats 121
drug, host and vector interactions 133
horses 119–21
pigs 118, 119
relapse infections 131–3
relapse treatment 122
resistance to drugs 128–33
serological diagnosis 114, 115
sheep and goats 118

Ureidosuccinic acid 386
analogues 389–91
Uridine-5′-phosphate inhibitors and synthesis 386

Vaccine, toxoid 251
Vascular permeability reaction (VPR)
Bacillus cereus toxins 484, 485, 489
and hemolysins 470–3
Viral infections and interferon
economic importance, treatment 23, 24
persistent, chronic 24, 25
role in pathogenesis 30, 31
Virus, interferon effects in animals
hepatitis B 23
herpes simplex 2–5, 18–20
and interferon sensitivity 25, 26
picornavirus 10–14
rabies 21–3
togavirus 14–17
vaccinia 4–7, 17, 18
vesicular stomatitis 20, 21

Wax esters in pig epidermis 361